Fulvestrant
FDA-approved product (solution, intramuscular), marketed as Cligavyx, Faslodex, Fulvestrant.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Cancer
- HER2 Positive Breast Carcinoma
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Anti-estrogens
- FDA pharmacologic class
- Estrogen Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA59.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fulvestrant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917 · start 2026-01-26
Registered record
- Registry ID
- NCT07287917
- Conditions
- Melanoma (Skin Cancer); HER2-low Hormone Receptor Positive Breast Cancer
- Interventions
- AMXT 1501 Dicaprate; DFMO; Fulvestrant; Capivasertib; Pembrolizumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2026-01-26
- Completion
- 2028-12-29
- Enrolment
- 92
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMelanoma (Skin Cancer); HER2-low Hormone Receptor Positive Breast CancerInterventionAMXT 1501 Dicaprate; DFMO; Fulvestrant; Capivasertib +1 morePhasePhase 1 / Phase 2Registry statusRecruitingEfficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
NCT07037199 · start 2025-08-18
Registered record
- Registry ID
- NCT07037199
- Conditions
- Advanced Breast Cancer
- Interventions
- Trastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-08-18
- Completion
- 2030-06-30
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Breast CancerInterventionTrastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapyPhasePhase 2Registry statusRecruitingSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883 · start 2025-06-30
Registered record
- Registry ID
- NCT06486883
- Conditions
- Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma
- Interventions
- Trastuzumab deruxtecan (T-DXd, DS-8201a); CDK4/6i plus ET
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-06-30
- Completion
- 2028-01
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast CarcinomaInterventionTrastuzumab deruxtecan (T-DXd, DS-8201a); CDK4/6i plus ETPhasePhase 2Registry statusRecruitingClinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
NCT06851442 · start 2025-05-16
Registered record
- Registry ID
- NCT06851442
- Conditions
- Breast Cancer
- Interventions
- TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Terminated
- Start
- 2025-05-16
- Completion
- 2025-11-20
- Enrolment
- 8
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionTQB3912 tablets in combination with fulvestrant injection± TQB3616 capsulesPhasePhase 1 / Phase 2Registry statusTerminatedSNV4818 in Participants With Advanced Solid Tumors
NCT06736704 · start 2025-02-20
Registered record
- Registry ID
- NCT06736704
- Conditions
- Advanced Solid Tumors
- Interventions
- SNV4818; Fulvestrant; Palbociclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2025-02-20
- Completion
- 2027-06
- Enrolment
- 320
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Solid TumorsInterventionSNV4818; Fulvestrant; PalbociclibPhasePhase 1 / Phase 2Registry statusRecruitingA Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921 · start 2024-11-14
Registered record
- Registry ID
- NCT06680921
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- SIM0270; Everolimus (Afinitor®); Exemestane tablets; Fulvestrant injection
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2024-11-14
- Completion
- 2028-08-31
- Enrolment
- 482
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLocally Advanced or Metastatic Breast CancerInterventionSIM0270; Everolimus (Afinitor®); Exemestane tablets; Fulvestrant injectionPhasePhase 3Registry statusActive not recruitingTesting the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
NCT05554354 · start 2024-09-13
Registered record
- Registry ID
- NCT05554354
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Binimetinib; Biopsy Procedure; Biospecimen Collection; Bone Scan; Computed Tomography; Echocardiography Test; Fulvestrant; Magnetic Resonance Imaging; Multigated Acquisition Scan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2024-09-13
- Completion
- 2025-04-04
- Enrolment
- 1
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast CarcinomaInterventionBinimetinib; Biopsy Procedure; Biospecimen Collection; Bone Scan +5 morePhasePhase 2Registry statusTerminatedEfficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
NCT05872347 · start 2023-09-19
Registered record
- Registry ID
- NCT05872347
- Conditions
- Breast Cancer Brain Metastases
- Interventions
- SPH4336 Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2023-09-19
- Completion
- 2026-12-31
- Enrolment
- 52
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer Brain MetastasesInterventionSPH4336 TabletsPhasePhase 2Registry statusRecruitingComparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
NCT05816655 · start 2023-05-31
Registered record
- Registry ID
- NCT05816655
- Conditions
- Metastatic Breast Cancer
- Interventions
- Fulvestrant plus AI plus ribociclib; AI plus ribociclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2023-05-31
- Completion
- 2029-06-30
- Enrolment
- 202
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Breast CancerInterventionFulvestrant plus AI plus ribociclib; AI plus ribociclibPhasePhase 2Registry statusRecruitingOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080 · start 2023-03-28
Registered record
- Registry ID
- NCT05735080
- Conditions
- Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer
- Interventions
- INX-315; Fulvestrant; Abemaciclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2023-03-28
- Completion
- 2027-09
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast +5 moreInterventionINX-315; Fulvestrant; AbemaciclibPhasePhase 1 / Phase 2Registry statusRecruitingPhase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
NCT05384119 · start 2023-01-09
Registered record
- Registry ID
- NCT05384119
- Conditions
- Breast Cancer
- Interventions
- TTI-101; Palbociclib; Aromatase inhibitor (AI); fulvestrant; ribociclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Terminated
- Start
- 2023-01-09
- Completion
- 2024-04-25
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionTTI-101; Palbociclib; Aromatase inhibitor (AI); fulvestrant +1 morePhasePhase 1Registry statusTerminatedEvaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
NCT05536128 · start 2022-12-31
Registered record
- Registry ID
- NCT05536128
- Conditions
- Advanced Breast Cancer
- Interventions
- Olaparib; Fulvestrant
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2022-12-31
- Completion
- 2025-12-31
- Enrolment
- 64
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Breast CancerInterventionOlaparib; FulvestrantPhasePhase 2Registry statusRecruitingAnastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT05524584 · start 2022-08-31
Registered record
- Registry ID
- NCT05524584
- Conditions
- Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer
- Interventions
- Fulvestrant; Anastrozole; Abemaciclib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2022-08-31
- Completion
- 2031-12-31
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast CancerInterventionFulvestrant; Anastrozole; AbemaciclibPhasePhase 2Registry statusRecruitingAn Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
NCT05186545 · start 2022-07-01
Registered record
- Registry ID
- NCT05186545
- Conditions
- Breast Cancer; Breast Cancer Female
- Interventions
- surufatinib + fulvestrant + chidamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2022-07-01
- Completion
- 2025-07
- Enrolment
- 63
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Breast Cancer FemaleInterventionsurufatinib + fulvestrant + chidamidePhasePhase 2Registry statusUnknownTreatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
NCT05328440 · start 2022-05-20
Registered record
- Registry ID
- NCT05328440
- Conditions
- Breast Neoplasms
- Interventions
- Pyrotinib Maleate; Dalpiciclib Isethionate Tablets; Inetetamab; Fulvestrant
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2022-05-20
- Completion
- 2026-01-01
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast NeoplasmsInterventionPyrotinib Maleate; Dalpiciclib Isethionate Tablets; Inetetamab; FulvestrantPhasePhase 2Registry statusUnknown